raloxifene hydrochloride has been researched along with Atherogenesis in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Babaahmadi-Rezaei, H; Mohammadtaghvaei, N; Rashidi, M; Zarezade, V | 1 |
| Guo, J; Huo, S; Li, C; Li, S; Lin, J; Lin, L; Liu, T; Luo, P; Lv, J; Ma, H; Shi, W; Wang, M; Wang, Y; Yan, D; Zhang, C | 1 |
| Azizian, H; Ebrahimi, MN; Karam, GA; Khaksari, M; Raji-Amirhasani, A; Sepehri, G | 1 |
| Araki, Y; Ichikawa, S; Itoh, T; Iwasaki, T; Kanai, H; Kanda, T; Kasama, S; Koizumi, A; Kumakura, H; Kurabayashi, M; Murakami, M; Saito, Y; Sakamaki, T; Sakamoto, H; Sawada, Y; Sumino, H; Takahashi, T; Takayama, Y | 1 |
| Akiyoshi, M; Kato, K; Kubota, T; Obayashi, S; Terauchi, M | 1 |
| Vestergaard, P | 1 |
| Karwowski, W; Myśliwiec, M; Naumnik, B; Szczepański, M | 1 |
| Cetinkaya Demir, B; Köse, C; Ozbilgin, K; Uyar, Y | 1 |
| Bjarnason, NH | 1 |
| Christodoulakos, GE; Creatsas, GC; Economou, EV; Kouskouni, EE; Lambrinoudaki, IV; Panoulis, CP; Papadias, C; Vitoratos, N; Vlachou, SA | 1 |
| Chen, Y; Lin, GP; Tan, Z; Wang, TH; Xiang, QL | 1 |
| Dhungana, B; Dowsett, SA; Feng, M; Hodis, HN; Keech, CA; Li, Y; Mack, WJ | 1 |
| Baetta, R; Bellosta, S; Cairoli, F; Canavesi, M; Comparato, C; Corsini, A; Eberini, I; Granata, A; Monetti, M; Puglisi, L | 1 |
| Chan, YC; Huang, Y; Leung, FP; Leung, HS; Tsang, SY; Wong, CM; Yao, X; Yung, LM | 1 |
| Bayram, M; Kabakci, N; Kalender, H; Kisa, U; Ozer, G; Ozkan, Y | 1 |
| Christodoulakos, GE; Creatsa, MG; Economou, EV; Kalligerou, I; Lambrinoudaki, IV; Panoulis, CP; Papadias, C; Siasou, Z | 1 |
| Badimon, JJ; Cardoso, L; Choi, BG; Fuster, V; Ibanez, B; Schaffler, MB; Tunstead, J; Vilahur, G; Viles-Gonzalez, JF; Yadegar, D; Zafar, MU | 1 |
2 review(s) available for raloxifene hydrochloride and Atherogenesis
| Article | Year |
|---|---|
The mechanism of vascular calcification - a systematic review.
Topics: Atherosclerosis; Calciphylaxis; Cardiovascular Diseases; Gonadal Steroid Hormones; Heart Valves; Humans; Metabolic Diseases; Models, Biological; Osteoporosis; Raloxifene Hydrochloride; Vascular Calcification | 2012 |
Raloxifene, tamoxifen and vascular tone.
Topics: Animals; Atherosclerosis; Blood Vessels; Cardiovascular Agents; Cardiovascular Diseases; Cerebrovascular Circulation; Collateral Circulation; Coronary Circulation; Endothelium, Vascular; Estrogen Replacement Therapy; Female; Humans; Nitric Oxide; Pulmonary Circulation; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Vasodilation | 2007 |
3 trial(s) available for raloxifene hydrochloride and Atherogenesis
| Article | Year |
|---|---|
Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene.
Topics: Adult; Androgens; Atherosclerosis; Biomarkers; Cardiovascular System; Chemokine CCL2; Chemokine CCL5; Chemotaxis; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Middle Aged; Norethindrone; Norethindrone Acetate; Norpregnenes; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2007 |
Carotid artery intima-media thickness after raloxifene treatment.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Bone Density Conservation Agents; Carotid Arteries; Female; Follow-Up Studies; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Proportional Hazards Models; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Tunica Media; Ultrasonography; Women's Health | 2007 |
Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women.
Topics: Adipokines; Adiponectin; Adult; Apoptosis; Atherosclerosis; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Fas Ligand Protein; fas Receptor; Female; Greece; Humans; Lipids; Medroxyprogesterone Acetate; Middle Aged; Norpregnenes; Postmenopause; Raloxifene Hydrochloride; Resistin; Selective Estrogen Receptor Modulators | 2008 |
12 other study(ies) available for raloxifene hydrochloride and Atherogenesis
| Article | Year |
|---|---|
Cardioprotective effect of tamoxifen and raloxifene: Preventing proteoglycan synthesis by modulating non-canonical TGF-β signalling through NADPH oxidase and ERK phosphorylation.
Topics: Atherosclerosis; Humans; NADPH Oxidases; Phosphorylation; Proteoglycans; Raloxifene Hydrochloride; Reactive Oxygen Species; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Transforming Growth Factor beta | 2023 |
Raloxifene inhibits IL-6/STAT3 signaling pathway and protects against high-fat-induced atherosclerosis in ApoE
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cell Movement; Cell Survival; Cells, Cultured; Diet, High-Fat; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Interleukin-6; Male; Mice; Mice, Knockout; Plaque, Atherosclerotic; Raloxifene Hydrochloride; Rats; RAW 264.7 Cells; Signal Transduction; STAT3 Transcription Factor | 2020 |
The effects of alone and combination tamoxifen, raloxifene and estrogen on lipid profile and atherogenic index of ovariectomized type 2 diabetic rats.
Topics: Animals; Atherosclerosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Estrogens; Female; Lipids; Menopause; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Streptozocin; Tamoxifen | 2020 |
Effects of raloxifene on brachial arterial endothelial function, carotid wall thickness, and arterial stiffness in osteoporotic postmenopausal women.
Topics: Aged; Atherosclerosis; Blood Glucose; Blood Pressure; Bone Density; Brachial Artery; Carotid Arteries; Endothelium, Vascular; Estradiol; Female; Follicle Stimulating Hormone; Heart Rate; Humans; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis; Pulse; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vasodilation | 2010 |
Raloxifene temporarily reduces arterial stiffness.
Topics: Aged; Ankle Brachial Index; Arteries; Atherosclerosis; Bone Diseases, Metabolic; Case-Control Studies; Elasticity; Female; Humans; Linear Models; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2010 |
Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones?
Topics: Aged; Alendronate; Atherosclerosis; Bone Density Conservation Agents; Calcium; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Myocardial Infarction; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies | 2012 |
Effect of raloxifene and atorvastatin in atherosclerotic process in ovariectomized rats.
Topics: Animals; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Chemokine CCL2; Endothelium, Vascular; Estrogen Antagonists; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Ovariectomy; Pyrroles; Raloxifene Hydrochloride; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2013 |
Differential effects of alternatives to hormone replacement therapy in postmenopausal healthy women.
Topics: Animals; Atherosclerosis; Bone and Bones; Cardiovascular System; Estrogen Replacement Therapy; Estrogens; Female; Humans; Middle Aged; Norpregnenes; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2005 |
Effects of selective estrogen receptor modulator raloxifene plus 17-beta estradiol in aorta and mammary gland of female experimental atherosclerosis rabbits and possible involvement of ERK signal transduction pathway.
Topics: Animals; Aorta; Atherosclerosis; Blotting, Western; Drug Interactions; Estradiol; Extracellular Signal-Regulated MAP Kinases; Female; Hyperplasia; Lipids; Mammary Glands, Animal; Muscle, Smooth, Vascular; Rabbits; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Signal Transduction; Tetrazolium Salts; Thiazoles; Thymidine | 2006 |
Raloxifene inhibits matrix metalloproteinases expression and activity in macrophages and smooth muscle cells.
Topics: Animals; Atherosclerosis; Carotid Arteries; Cells, Cultured; CHO Cells; Cholesterol, Dietary; Cricetinae; Cricetulus; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Enzymologic; Humans; Macrophages; Macrophages, Peritoneal; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NF-kappa B; Ovariectomy; Promoter Regions, Genetic; Protease Inhibitors; Rabbits; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Transcription, Genetic; Transfection | 2007 |
The effects of raloxifene and tibolone on homocysteine and vascular histopathological changes.
Topics: Animals; Atherosclerosis; Carotid Arteries; Estrogen Replacement Therapy; Female; Folic Acid; Homocysteine; Norpregnenes; Raloxifene Hydrochloride; Rats; Rats, Wistar; Vitamin B 12 | 2007 |
Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model.
Topics: Animals; Atherosclerosis; Chemokine CCL2; Cyclooxygenase 2; Disease Models, Animal; Female; Magnetic Resonance Imaging; Matrix Metalloproteinase 1; Menopause; Osteoporosis; Ovariectomy; Rabbits; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2008 |